FibroBiologics (Direct Listing)
Note: This is NOT an IPO. This is a NASDAQ direct listing. The trade date is Jan. 31, 2024, according to the prospectus. Maxim Group is the financial advisor. There is no underwriter. We are a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant […]
January 25, 2024 Read More